Narayana Hrudayalaya Limited (NH) Fair Value & Analysis

Healthcare · IN · Market cap ₹369B

A solid business, but screening 77% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (₹733.40). The favourable scenario is already priced in.
• The model range is unusually wide (₹227.00 to ₹733.40). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range ₹386.82 – ₹2,260 · fair‑value band ₹227.00 – ₹733.40 · the ₹1,816 price screens above the ₹412.77 fair value. Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Narayana Hrudayalaya Limited (NH) currently trades at ₹1,816, while our model-based Fair Value estimate is ₹412.77, implying the stock looks roughly 77.3% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Narayana Hrudayalaya Limited generated revenue of ₹59.6B at a net margin of 14.2%. Revenue grew 17.4% year over year. It earns a return on equity of 23.2%. Net debt stands at ₹41.0B. Fundamentals as of Aug 22, 2026

Our scenario range runs from ₹227.00 (bear case) to ₹733.40 (bull case); at ₹1,816, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at -77%, NH screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (₹674.31) versus Asset-Based (₹149.68). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Narayana Hrudayalaya Limited engages in the medical and healthcare services in India and internationally. It operates through two segments, Medical and Healthcare Related Services; and Others. The company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centres, nursing homes and other related activities.

Full company description

Narayana Hrudayalaya Limited engages in the medical and healthcare services in India and internationally. It operates through two segments, Medical and Healthcare Related Services; and Others. The company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centres, nursing homes and other related activities. It offers cardiology, cardiac surgery, nephrology, urology, neurology, neuro-surgery, endocrinology, orthopedics, internal medicines, obstetrics, gynecology, pediatrics, neonatology, gastroenterology, and oncology services. The company engages in health insurance business. The company was incorporated in 2000 and is headquartered in Bengaluru, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Narayana Hrudayalaya Limited reported revenue of ₹78.6B in FY2025 versus ₹91.9B in FY2021, a compound −3.8%/yr. Reported net income was ₹8.1B in FY2025, compounding −35.8%/yr from FY2021.

NH screens 77% overvalued. Compare with HCA Healthcare, Inc →

Peer Group

Medical Care Facilities · 268 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.